Table 4.

Scenarios: OPAT outpatient versus inpatient stay

	Scenario	Base case
0	Base case (outpatient)
1	Using cost of inpatient care in infectious disease unit (ISD Scotland)14	Using condition-specific healthcare resource group costs15
2	Using ISD Scotland14 cost for outpatient appointments and inpatient stay (IDU)	Using microcosting of nurse and consultant outpatient appointments
3	Assuming overheads are 44.8% of total costs consistent with a published source16	Assuming per day cost of using healthcare services consistent with a published source8
4	Using BNF12 as a source for the cost of linezolid (orthopaedic and diabetic foot infections)	Using eMIT13 as a source for the cost of linezolid (orthopaedic and diabetic foot infections)
Skin and soft-tissue infections only
5	Including the cost of consultant time	Nurse-led condition; no consultant time
6	Using the licensed dose of dalbavancin (1.5 g) once off	Using dalbavancin 1 g as a once-off treatment consistent with clinical practice
7	Using the licensed dose of dalbavancin 1 g followed by 0.5 g	Using dalbavancin 1 g as a once-off treatment consistent with clinical practice

BNF, British National Formulary; eMIT, electronic market information tool; IDU, infectious disease unit; ISD, information services division; OPAT, outpatient parenteral antimicrobial therapy.